ClinConnect ClinConnect Logo
Search / Trial NCT05162508

Impact of COVID-19 SARS-CoV-2 Variability in ICU Hospitalized Patients With Severe Disease

Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Dec 10, 2021

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is focused on understanding how different versions of the COVID-19 virus, known as variants, affect patients who are seriously ill and hospitalized in intensive care units (ICUs). Researchers want to find out if specific changes in the virus's genetic makeup relate to how severe a patient’s illness becomes and their overall recovery. By studying these relationships, the trial aims to gather important information that could help improve treatment and control measures for COVID-19 in the future.

To be eligible for the trial, participants must be at least 18 years old and have tested positive for COVID-19 with a specific test result. They should also be admitted to the ICU due to severe breathing difficulties. The study will take place over a total of 28 days for each participant, with a longer overall duration for the trial itself. If you or a family member are considering participating, you can expect to provide a sample from your nose and have regular observations during your hospital stay. This research could play a vital role in understanding how new variants of the virus impact health outcomes for serious COVID-19 cases.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Age ≥ 18 years.
  • Availability of nasopharyngeal swab from SOC
  • SARS-CoV-2 infection as assessed by a positive RT-PCR test (CT \< 32), including in SARS CoV-2 vaccinated or previously infected patients
  • Patient admitted in the ICU for acute respiratory failure (SpO2 ≤ 90% and need for supplemental oxygen or any kind of ventilator support; i.e., OMS 10-category ordinal scale ≥5)
  • Patient or trusted person or close or relative, And, accepting study participation
  • Exclusion Criteria:
  • Patient with SARS-CoV-2 infection but no acute respiratory failure
  • Patient deprived of liberty or under legal protection (guardianship, curators, legal protection, forced hospitalization)

About Assistance Publique Hôpitaux De Paris

Assistance Publique - Hôpitaux de Paris (AP-HP) is a leading public hospital system in France, renowned for its commitment to healthcare excellence and innovative medical research. As a prominent clinical trial sponsor, AP-HP plays a pivotal role in advancing medical knowledge and improving patient care through rigorous scientific investigations across a wide range of therapeutic areas. With a focus on collaboration and interdisciplinary approaches, AP-HP leverages its extensive network of hospitals and expert clinicians to facilitate high-quality clinical trials that adhere to the highest ethical and regulatory standards, ultimately aiming to translate research findings into tangible health benefits for diverse patient populations.

Locations

Créteil, Val De Marne, France

Patients applied

0 patients applied

Trial Officials

Slim FOURATI, MD-PHD

Principal Investigator

Assistance Publique - Hôpitaux de Paris (AP-HP) Henri Mondor

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials